76
|
Duruisseaux M, Mc Leer-Florin A, Moro-Sibilot D, Cadranel J. Are ALK rearrangement variants promising predictive biomarker of ALK tyrosine kinase inhibitors efficacy? Ann Oncol 2017; 28:1401. [DOI: 10.1093/annonc/mdx116] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
77
|
Godet C, Couturaud F, Ragot S, Laurent F, Brun AL, Bergeron A, Cadranel J. [Allergic bronchopulmonary aspergillosis: Evaluation of a maintenance therapy with nebulized Ambisome ®]. Rev Mal Respir 2017; 34:581-587. [PMID: 28552257 DOI: 10.1016/j.rmr.2017.04.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2017] [Accepted: 01/25/2017] [Indexed: 11/26/2022]
Abstract
BACKGROUND Allergic bronchopulmonary aspergillosis (ABPA) affects 3-13% of patients with asthma. Its natural history includes possibly life-threatening exacerbations and evolution towards fixed obstructive ventilatory disorders or even irreversible lung fibrosis lesions. ABPA prognosis is directly associated with exacerbation control and the main objective of the treatment is to decrease their frequency and duration. Recommendations regarding dosage and duration of treatment are not very precise. The currently used combination of itraconazole and corticosteroid therapy has many limitations. The interests of a therapeutic strategy using nebulized liposomal amphotericin B (LAmB) are to heighten antifungal lung tissue concentration, to circumvent drug interactions and decrease the potential toxicity of systemic antifungal treatments. Finally, this association leads to improved eradication of Aspergillus, thereby limiting the risk of side effects and the emergence of treatment-resistant Aspergillus strains. METHODS This is a phase II, multicentre, randomized, single blind, controlled therapeutic study, with the objective of comparing the potential benefit on exacerbation control of a maintenance therapy by LAmB nebulization. The main objective of the study is to compare the incidence of severe clinical exacerbations in ABPA treatment, between a maintenance treatment strategy with nebulized LAmB and a conventional strategy without antifungal maintenance therapy. EXPECTED RESULTS The results will guide practitioners in the management of ABPA treatments and help to define the place of aerosols of LAmB on "evidence base medicine" criteria.
Collapse
|
78
|
Duruisseaux M, Besse B, Cadranel J, Pérol M, Mennecier B, Bigay-Game L, Descourt R, Dansin E, Audigier-Valette C, Moreau L, Hureaux J, Veillon R, Otto J, Madroszyk-Flandin A, Cortot A, Guichard F, Boudou-Rouquette P, Langlais A, Missy P, Morin F, Moro-Sibilot D. Efficacité du bévacizumab associé à un doublet de chimiothérapie à base de sels de platine en première ligne de traitement des cancers du poumon ALK-réarrangés : analyse des données de l’étude IFCT-1302 CLINALK. Rev Mal Respir 2017. [DOI: 10.1016/j.rmr.2016.10.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
79
|
Gibiot Q, Monnet I, Brun AL, Issoufaly T, Jabot L, Rozensztajn N, Vinas F, Wislez M, Chouaid C, Cadranel J, Naccache JM. Pneumopathies interstitielles diffuses au cours des cancers pulmonaires. Rev Mal Respir 2017. [DOI: 10.1016/j.rmr.2016.10.033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
80
|
Duchemann B, Annesi-Maesano I, De Naurois CJ, Crestani B, Cadranel J, Rosental P, Valeyre D, Nunes H. Impact des facteurs démographiques sur l’étiologie des PID. Rev Mal Respir 2017. [DOI: 10.1016/j.rmr.2016.10.141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
81
|
Delaunay M, Cadranel J, Meyer N, Lusque A, Zalcman G, Moro-Sibilot D, Michot J, Raimbourg J, Girard N, Thiberville L, Planchard D, Metivier A, Barlesi F, Dansin E, Perol M, Pichon E, Fumet J, Gounant V, Collot S, Jaffro M, Prévot G, Milia J, Mazieres J. Pathologie pulmonaire infiltrative diffuse survenant chez des patients traités par les inhibiteurs des points de contrôle immunitaire (immunothérapie). Rev Mal Respir 2017. [DOI: 10.1016/j.rmr.2016.10.119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
82
|
Cadranel J, Quoix E, Duruisseaux M, Friard S, Wislez M, Daniel C, Fabre E, Madroszyk A, Westeel V, Merle P, Léna H, Dansin E, Mazieres J, Scherpereel A, Hiret S, Kaderbhai C, Souquet PJ, Missy P, Langlais A, Morin F, Zalcman G, Moro-Sibilot D, Barlesi F. Impact pronostique du choix de la première ligne thérapeutique et de la connaissance des résultats des biomarqueurs chez les malades atteints de cancers bronchiques non à petites cellules (CBNPC) étendus en France : résultats de l’étude IFCT PREDICT.amm. Rev Mal Respir 2017. [DOI: 10.1016/j.rmr.2016.10.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
83
|
Canellas A, Parrot A, Hachem M, Cadranel J, Fartoukh M. Étude descriptive de l’insuffisance respiratoire aiguë des patients ayant un cancer bronchopulmonaire admis en réanimation : étude DIREA. Rev Mal Respir 2017. [DOI: 10.1016/j.rmr.2016.10.116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
84
|
Fallet V, Saffroy R, Girard N, Mazières J, Moro-Sibilot D, Lantuejoul S, Rouquette I, Thivolet-Bejui F, Vieira T, Antoine M, Cadranel J, Lemoine A, Wislez M. Recherche de mutation de l’exon 14 de MET au sein des carcinomes sarcomatoïdes pulmonaires : étude multicentrique rétrospective. Rev Mal Respir 2017. [DOI: 10.1016/j.rmr.2016.10.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
85
|
Crequit P, Cadranel J, Trinquart L, Ravaud P. Les traitements de 2e ligne du cancer bronchique non à petites cellules (CBNPC) avancé EGFR sauvage ou de statut inconnu : revue systémique et méta-analyse en réseau. Rev Mal Respir 2017. [DOI: 10.1016/j.rmr.2016.10.477] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
86
|
Canellas A, Crequit P, Duruisseaux M, Fillon J, Rozensztajn N, Vieira T, Ruppert A, Baud M, Poulot V, Mathiot N, Antoine M, Fallet V, Lavole A, Wislez M, Cadranel J. Efficacité et tolérance de l’adjonction de bévacizumab à une chimiothérapie par carboplatine-paclitaxel chez des patients présentant un adénocarcinome pulmonaire lépidique de stade avancé : une étude de cohorte observationnelle rétrospective. Rev Mal Respir 2017. [DOI: 10.1016/j.rmr.2016.10.118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
87
|
Crequit P, Trinquart L, Cadranel J, Ravaud P. La méta-analyse en réseau cumulative et dynamique : un nouvel outil méthodologique pour adapter les traitements du CBNPC au quotidien ? Rev Mal Respir 2017. [DOI: 10.1016/j.rmr.2016.10.474] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
88
|
Cadranel J, Morere J, Fabre E, Lemaire B, Monnet I, Brambilla E, Rondeau V, Licour M, Perol M. Données en « vraie vie » de patients traités par gefitinib pour un cancer bronchique non à petites cellules localement avancé ou métastatique, avec mutation de l’EGFR : résultats de l’étude EPIDAURE. Rev Mal Respir 2017. [DOI: 10.1016/j.rmr.2016.10.471] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
89
|
Leduc C, Blons H, Besse B, Merlio J, Debieuvre D, Lemoine A, Monnet I, Pouessel D, Bringuier P, Poudenx M, Rouquette I, Vaylet F, Morin F, Langlais A, Quoix E, Zalcman G, Moro-Sibilot D, Cadranel J, Beau-Faller M, Barlesi F. Caractéristiques cliniques et moléculaires des patients atteints d’un cancer bronchique non à petites cellules (CBNPC) avec mutation de l’EGFR : étude ancillaire de l’étude IFCT biomarqueurs France. Rev Mal Respir 2017. [DOI: 10.1016/j.rmr.2016.10.108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
90
|
Mirouse A, Parrot A, De Prost N, Mariotte E, Demoule A, Bréchot N, Vautier M, Bige N, De Montmollin E, Cadranel J, Cacoub P, Saadoun D. Caractéristiques, traitement et évolution des hémorragies intra-alvéolaires de cause immune sévères : étude française multicentrique. Rev Med Interne 2016. [DOI: 10.1016/j.revmed.2016.10.061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
91
|
Planchard D, Pérol M, Quantin X, Cortot A, Cadranel J, Schott R, Dansin E, Fraboulet G, Moro-Sibilot D, Soria JC, Mazieres J, Moulec S, Coudurier M, Pichon E, Licour M, Maribas D, Gourion A, Radu N, Varoqueaux N, Chouaid C. Osimertinib in EGFR T790M positive advanced NSCLC (aNSCLC) – real–life data from the French temporary authorization for use (ATU) program. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw383.34] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
92
|
Drezet A, Loubière S, Wislez M, Beau-Faller M, Nanni-Métellus I, Garcia S, Chenard MP, Ghnassia JP, Lacave R, Antoine M, Duruisseaux M, Friard S, Fabre E, Daniel C, Missy P, Morin F, Barlesi F, Auquier P, Cadranel J. Cost-effectiveness of KRAS, EGFR and ALK testing for therapeutic decision making of advanced stage non-small cell lung cancer (NSCLC): the French IFCT-PREDICT.amm study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw383.11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
93
|
Wislez M, Domblides C, Antoine M, Hamard C, Rabbe N, Rodenas A, Vieira T, Créquit P, Cadranel J, Lavolé A. PD-L1 expression and tumor immune-cell infiltration in non-small cell lung cancer from HIV-infected patients. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw363.29] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
94
|
Leduc C, Blons H, Besse B, Merlio JP, Debieuvre D, Lemoine A, Monnet I, Pouessel D, Bringuier P, Poudenx M, Rouquette I, Vaylet F, Morin F, Langlais A, Quoix E, Zalcman G, Moro-Sibilot D, Cadranel J, Beau-Faller M, Barlesi F. Clinical and biological characteristics of non-small cell lung cancer (NSCLC) harbouring EGFR mutation: Results of the nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw383.02] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
95
|
Perol M, Morère JF, Fabre E, Lemaire B, Monnet I, Brambilla E, Rondeau V, Licour M, Cadranel J. French real-life efficacy of 1st line gefitinib in EGFR mutation-positive NSCLC in the prospective EPIDAURE study: Results by EGFR exon 19 Del and L858R mutation subtypes. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw383.44] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
96
|
Perkins G, Fabre E, Fallet V, Blons H, Pecuchet N, Gounant V, Gibault L, Michel-Jeljeli E, Antoine M, Roux E, Wislez M, Le Corre D, Leroy K, Lacave R, Taieb J, Cadranel J, Laurent-Puig P. Whole exome sequencing (WES) and RNA sequencing (RNA-seq) in routine clinical practice for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) patients (pts). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw363.44] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
97
|
Gounant V, Brosseau S, Naltet C, Opsomer MA, Antoine M, Danel C, Khalil A, Cadranel J, Zalcman G. Nivolumab-induced organizing pneumonitis in a patient with lung sarcomatoid carcinoma. Lung Cancer 2016; 99:162-5. [PMID: 27565934 DOI: 10.1016/j.lungcan.2016.07.010] [Citation(s) in RCA: 35] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2016] [Revised: 07/09/2016] [Accepted: 07/11/2016] [Indexed: 12/28/2022]
Abstract
Immune checkpoint inhibitors are known to induce 'immune pneumonitis' in 3-6% of patients treated for lung cancer. However, their dramatic efficacy in as much as 20% of patients led to recent registrations in squamous, and then non-squamous lung carcinoma, in second line setting after failure of first-line chemotherapy, while large phase 3 trials are on-going, to assess first-line immunotherapy, either alone or in combination with chemotherapy. Pulmonary Sarcomatoid carcinomas consist of a rare subset of highly aggressive and poorly differentiated non-small-cell lung carcinomas (NSCLC), with poor prognosis and chemo-resistance. Although exhibiting high expression of programmed death ligand-1 (PD-L1), their sensitivity to inhibitors of PD-1/PD-L1 axis is still unknown. Here we report a case of lung sarcomatoid carcinoma with Nivolumab dramatic and long-lasting efficacy, but occurrence of a very specific pattern of lung toxicity, the so-called 'organizing bronchiolitis syndrome'. As more and more NSCLC patients are promised to receive PD-1 inhibitors as part of their treatment, we feel that specific features of such Nivolumab-induced organizing pneumonitis should be known. Although corticosteroid sensitivity is high, recurrence is frequent because of premature steroid tapering, as for all other causes of organizing pneumonias, and probably because of the Nivolumab long tissue half-life.
Collapse
|
98
|
Marques C, Prôvot F, Matignon M, Boffa J, Hertig A, Touzot M, Belenfant X, Annane D, Quéméneur T, Cadranel J, Cacoub P, Saadoun D. Étude observationnelle multicentrique sur la maladie des anticorps anti-membrane basale glomérulaire (syndrome de Goodpasture). Rev Med Interne 2016. [DOI: 10.1016/j.revmed.2016.04.246] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
99
|
Cadranel J, Brambilla E, Morere J, Rondeau V, Fabre E, Lemaire B, Monnet I, Licour M, Perol M. 168P: Real life practice of gefitinib in patients (pts) with non-small-cell lung cancer (NSCLC) depending on epidermal growth factor receptor (EGFR) mutation status: Results from the prospective EPIDAURE study. J Thorac Oncol 2016. [DOI: 10.1016/s1556-0864(16)30278-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
100
|
Fennell DA, Summers Y, Cadranel J, Benepal T, Christoph DC, Lal R, Das M, Maxwell F, Visseren-Grul C, Ferry D. Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer. Cancer Treat Rev 2016; 44:42-50. [PMID: 26866673 DOI: 10.1016/j.ctrv.2016.01.003] [Citation(s) in RCA: 261] [Impact Index Per Article: 32.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2015] [Revised: 01/12/2016] [Accepted: 01/15/2016] [Indexed: 01/25/2023]
Abstract
The treatment of advanced non-small cell lung cancer (NSCLC) may be changing, but the cisplatin-based doublet remains the foundation of treatment for the majority of patients with advanced NSCLC. In this respect, changes in practice to various aspects of cisplatin use, such as administration schedules and the choice of methods and frequency of monitoring for toxicities, have contributed to an incremental improvement in patient management and experience. Chemoresistance, however, limits the clinical utility of this drug in patients with advanced NSCLC. Better understanding of the molecular mechanisms of cisplatin resistance, identification of predictive markers and the development of newer, more effective and less toxic platinum agents is required. In addition to maximising potential benefits from advances in molecular biology and associated therapeutics, modification of existing cisplatin-based treatments can still lead to improvements in patient outcomes and experiences.
Collapse
|